New rabies vaccine may require only a single shot... not 6September 21, 2009The current standard post-exposure regimen is not feasible in the developing world, where rabies is endemic (PHILADELPHIA) A person, usually a child, dies of rabies every 20 minutes. However, only one inoculation may be all it takes for rabies vaccination, according to new research published in the Journal of Infectious Diseases by researchers at the Jefferson Vaccine Center. A replication-deficient rabies virus vaccine that lacks a key gene called the matrix (M) gene induced a rapid and efficient anti-rabies immune response in mice and non-human primates, according to James McGettigan, Ph.D., assistant professor of Microbiology and Immunology at Jefferson Medical College of Thomas Jefferson University. "The M gene is one of the central genes of the rabies virus, and its absence inhibits the virus from completing its life cycle," Dr. McGettigan said. "The virus in the vaccine infects cells and induces an immune response, but the virus is deficient in spreading." The immune response induced with this process is so substantial that only one inoculation may be sufficient enough, according to Dr. McGettigan. In addition, the vaccine appears to be efficient in both pre-exposure and post-exposure settings. Currently, the World Health Organization standard for rabies infection is post-exposure prophylaxis. The complex regimen in the United States requires six different shots over 28 days: five of the rabies vaccine and one of rabies immunoglobulin. The current standard vaccine is made from inactivated rabies virus, whereas the experimental vaccine is made from a live rabies virus. The virus is modified by removing the M gene, thus inhibiting its spread within the vaccine recipient. Worldwide, the annual number of rabies-related deaths is estimated to be 40,000 to 70,000. The disease is endemic in developing areas, where the six-shot post-exposure regimen is not feasible for many people due to cost and availability. According to the World Health Organization, approximately 10 million people worldwide receive the post-exposure regimen, which presents a financial burden to both industrialized and developing countries. "Developing countries do not have the resources to vaccinate people six times after exposure, so many of these 10 million do not receive the full regimen," Dr. McGettigan said. "Therefore, simpler and less expensive vaccine regimens are needed. The alternative may also be to treat people pre-exposure, as they are with many of the current vaccines used. Although our vaccine was tested primarily to be a post-exposure vaccine, the data we collected show it would be effective as a pre-exposure vaccine as well." Thomas Jefferson University |
|||||||||||||||||||||
| Related Rabies Current Events and Rabies News Articles First human gets new antibody aimed at rabies virus MassBiologics of the University of Massachusetts Medical School today announced the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody (MAB) developed to neutralize the rabies virus. Rabies deaths from dog bites could be eliminated Someone in the developing world - particularly in rural Africa - dies from a rabid dog bite every 10 minutes. CSHL researchers pinpoint structure-building role for 2 non-coding RNAs Most of the DNA in the nucleus of each of our cells is converted into RNA, but only a small fraction of these RNA molecules serve as coding templates for the synthesis of proteins. Hope for a rabies eradication strategy in Africa Most of the rabies virus circulating in dogs in western and central Africa comes from a common ancestor introduced to the continent around 200 years ago, probably by European colonialists. Evolution of new brain area enables complex movements A new area of the cerebral cortex has evolved to enable man and higher primates to pick up small objects and deftly use tools, according to neuroscientists at the University of Pittsburgh School of Medicine and Pittsburgh's Veterans Affairs Medical Center. Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today reported publication of data in Nature Medicine that supports the broad anti-viral potential of the company's novel anti-phosphatidylserine (anti-PS) antibody platform, showing that its PS-targeting drug bavituximab can cure lethal virus infections in animal disease models. UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents. China sees spike in rabies cases A new Chinese study has reported a dramatic spike in rabies infections. The research, published today in the open access journal BMC Infectious Diseases, shows that in some provinces of China the number of human rabies cases has jumped dramatically since the new millennium. Different type of colon cancer vaccine reduces disease spread, Jefferson scientists show Taking advantage of the fact that the intestines have a separate immune system from the rest of the body, scientists at the Kimmel Cancer Center at Jefferson in Philadelphia have found a way to immunize mice against the development of metastatic disease. A simplified method of giving rabies vaccine A simplified economical method of giving rabies vaccine is just as effective as the expensive standard vaccine regimen at stimulating anti-rabies antibodies. More Rabies Current Events and Rabies News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||